• 1
    Dykes DD, Miller SA, Polesky HF. Distribution of alpha 1-antitrypsin variants in a US white population. Hum Hered. 1984;34: 30810.
  • 2
    Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, PiZ. Acta Med Scand. 1978;204: 34551.
  • 3
    Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. Am J Transplant. 2006;6: 121227.
  • 4
    Davis SQ, Garrity ER Jr. Organ allocation in lung transplant. Chest. 2007;132: 164651.
  • 5
    American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168: 818900.
  • 6
    Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT, National Emphysema Treatment Trial Research Group. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg. 2007;83: 24151.
  • 7
    Wan IY, Toma TP, Geddes DM, Snell G, Williams T, Venuta F, Yim AP. Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients. Chest. 2006;129: 51826.
  • 8
    Ingenito EP, Wood DE, Utz JP. Bronchoscopic lung volume reduction in severe emphysema. Proc Am Thorac Soc. 2008;5: 45460.
  • 9
    Sciurba Frank C, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, Kovitz KL, Chiacchierini RP, Goldin J. McLennan G. For the VENT study research group. ‘A randomised study of endobronchial valves for advanced emphysema’. N Engl J Med. 2010;363(13): 123344.
  • 10
    Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173: 1390413.
  • 11
    Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26: 31938.
  • 12
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166: 1117.
  • 13
    Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31: 41669.
  • 14
    Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation – the St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145: 13217.
  • 15
    Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93: 5806.
  • 16
    Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350: 100512.
  • 17
    Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med. 2008;178: 4919.
  • 18
    Venuta F, Rendina EA, De Giacomo T, Anile M, Diso D, Andreetti C, Pugliese F, Coloni GF. Bronchoscopic procedures for emphysema treatment. Eur J Cardiothorac Surg. 2006;29: 2817.
  • 19
    National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001;345: 107583.
  • 20
    Herpel LB, Kanner RE, Lee SM, Fessler HE, Sciurba FC, Connett JE, Wise RA. Variability of spirometry in chronic obstructive pulmonary disease: results from two clinical trials. Am J Respir Crit Care Med. 2006;173: 110613.
  • 21
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;4: 3328.